GLP-1s Explained: Beyond the Weightloss with Dr. Kimberly Ferrero
About this episode
Dr. Kimberly Ferrero discusses the broader implications of GLP-1 medications beyond weight loss.
GLP-1 medications like Ozempic and Wegovy are making headlines for weight loss, but their potential impact goes far beyond the numbers on a scale. Could these drugs reshape health care spending, insurance coverage, longevity, and even the assumptions actuaries use to model risk? In this episode of Actuary Voices, Contingencies Editor-in-Chief Preeti Vasishtha speaks with Dr. Kimberly Ferrero, the American Academy of Actuaries' Assistant Director of Research. Drawing on her background in cardiovascular and metabolic disease research, Dr. Ferrero explores the science behind GLP-1 therapies, the promises and uncertainties surrounding their long-term effects, and why actuaries are watching their rapid adoption so closely. The conversation examines affordability, insurer costs, mortality assumptions, patient behavior, health equity, and the question at the center of today's debate: Will the impressive results seen in clinical trials translate into lasting improvements at the population level? Additional Resources: Read Dr. Ferrero's article: How GLP-1 Drugs Are Shaping Care, Cost, and Coverage . Learn More About How Weightloss Drugs Effect Health care Costs in the Drivers of 2026…
More episodes of Actuary Voices
- The Hidden Cost of Complexity: Pietro Parodi on Smarter Actuarial Models
- Hidden to Heard: Transgender Visibility and the Power of Data with Cynthia Edwalds
- Policy Update: Tariffs, Inflation, and Rising Auto Insurance Costs
- Leading the Actuarial Profession Forward: Insights from Tricia Matson
Explore listener stats, chart rankings, contacts and more on the Actuary Voices podcast page.